Advertisement
UK markets closed
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • HANG SENG

    18,479.37
    -98.93 (-0.53%)
     
  • CRUDE OIL

    78.92
    +0.44 (+0.56%)
     
  • GOLD FUTURES

    2,321.80
    -9.40 (-0.40%)
     
  • DOW

    38,929.38
    +77.11 (+0.20%)
     
  • Bitcoin GBP

    50,770.38
    +106.52 (+0.21%)
     
  • CMC Crypto 200

    1,316.02
    -49.11 (-3.60%)
     
  • NASDAQ Composite

    16,389.81
    +40.57 (+0.25%)
     
  • UK FTSE All Share

    4,522.99
    +53.90 (+1.21%)
     

Revvity Board Declares Quarterly Dividend

WALTHAM, Mass., April 25, 2024--(BUSINESS WIRE)--The Board of Directors of Revvity (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on August 9, 2024 to all shareholders of record at the close of business on July 19, 2024.

About Revvity 
At Revvity, "impossible" is inspiration, and "can’t be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2023 revenue of more than $2.7 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

ADVERTISEMENT

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240425424317/en/

Contacts

Media Relations:
Chet Murray
(781) 462-5126
chet.murray@revvity.com

Investor Relations:
Steve Willoughby
steve.willoughby@revvity.com